Treatment Plan for BPH According to Stage
For men over 50 with lower urinary tract symptoms (LUTS), treatment should be stratified based on symptom severity using the International Prostate Symptom Score (IPSS): mild symptoms (IPSS ≤7) warrant watchful waiting with lifestyle modifications; moderate-to-severe symptoms (IPSS >8) require alpha-blockers as first-line therapy, with 5-alpha reductase inhibitors added for prostates >30cc; and complicated disease (acute urinary retention, recurrent infections, bladder stones, renal impairment) mandates surgical intervention. 1
Clinical Features for Diagnosis
Mandatory Initial Assessment 2, 1, 2
Medical history focusing on:
- Nature, duration, and severity of voiding symptoms (hesitancy, weak stream, incomplete emptying)
- Storage symptoms (frequency, urgency, nocturia)
- Degree of bother and impact on quality of life
- Previous genitourinary procedures
- Sexual function history
- Current medications (especially anticholinergics, diuretics)
Physical examination:
- Digital rectal examination (DRE) to assess prostate size, consistency, nodules, and tenderness
- Palpable bladder suggesting retention
- Neurological examination if indicated
Quantitative symptom assessment:
- International Prostate Symptom Score (IPSS) - mandatory for grading severity
- Quality of Life (QoL) index score ≥3 indicates bothersome symptoms 3
Laboratory tests:
Recommended Additional Tests 1, 2
- Uroflowmetry - maximum flow rate <12 mL/sec suggests obstruction
- Post-void residual urine (PVRU) - >100 mL indicates significant retention 3
- Prostate volume measurement by transabdominal ultrasound - critical for treatment selection
Optional Tests (Before Invasive Therapy) 5
- Pressure-flow urodynamic studies for unclear cases
- Ultrasound assessment of upper urinary tracts if renal impairment suspected
- Intravesical prostatic protrusion (IPP) measurement 3
Treatment Algorithm by Stage
Stage I: Mild Symptoms (IPSS ≤7) or Minimal Bother
Approach: Watchful Waiting with Active Surveillance 5, 6
Reassurance and patient education about natural history
Lifestyle modifications:
Follow-up: Annual reassessment with IPSS and symptom review 6
Pitfall: Don't dismiss mild symptoms if QoL is significantly impacted - bother matters more than score alone.
Stage II: Moderate-to-Severe Symptoms (IPSS >8) Without Complications
Approach: Medical Therapy 5, 1
First-Line: Alpha-Adrenergic Blockers 6, 1
Start with an alpha-blocker as initial monotherapy for all patients with bothersome moderate-to-severe LUTS. 1
Options:
- Tamsulosin 0.4 mg daily
- Alfuzosin 10 mg daily
- Silodosin 8 mg daily
- Doxazosin 1-8 mg daily (titrate)
- Terazosin 1-10 mg daily (titrate)
Mechanism: Relaxes prostatic smooth muscle (dynamic component)
Onset: Symptom improvement within days to weeks
Side effects: Orthostatic hypotension (especially doxazosin/terazosin), retrograde ejaculation (especially silodosin), intraoperative floppy iris syndrome 6
Clinical Pearl: If patient has concurrent erectile dysfunction, consider starting with tadalafil 5 mg daily as initial therapy instead 1
Add 5-Alpha Reductase Inhibitor (5ARI) if Prostate >30cc 1
For prostates >30cc on ultrasound or PSA suggesting enlargement, add a 5ARI to alpha-blocker therapy. 6
Options:
- Finasteride 5 mg daily
- Dutasteride 0.5 mg daily
Mechanism: Reduces prostate volume by blocking DHT conversion (static component)
Onset: 6-12 months for maximal effect
Benefits: Reduces disease progression, decreases risk of acute urinary retention and need for surgery 6
Side effects: Sexual dysfunction (decreased libido, erectile dysfunction), gynecomastia
Important: PSA levels decrease by ~50% after 6 months - must double PSA value when screening for prostate cancer 2
Combination Therapy: Alpha-Blocker + 5ARI 6
The CombAT study demonstrated that combination therapy with dutasteride plus tamsulosin provides superior symptom relief and reduces disease progression compared to monotherapy in men with prostates >30cc. 6
- Best evidence for doxazosin + finasteride combination 5
- Consider for patients with larger prostates (>40cc) and moderate-to-severe symptoms
- Reduces long-term risk of acute urinary retention by 66% compared to placebo 6
Alternative/Adjunctive Options 1
Phosphodiesterase-5 inhibitors (PDE5i):
- Tadalafil 5 mg daily - effective for LUTS with or without erectile dysfunction
- Can be used as monotherapy or with alpha-blockers
For predominant storage symptoms (urgency, frequency):
- Anticholinergics (if PVRU <100 mL and no retention risk)
- Beta-3 agonists (mirabegron 25-50 mg daily) - safer in men with elevated PVRU
Pitfall: Never use anticholinergics in men with significant post-void residual (>100-150 mL) - risk of acute retention.
Stage III: Refractory Symptoms or Incomplete Response to Medical Therapy
Approach: Minimally Invasive or Surgical Therapy 5, 1, 7
Indications for intervention:
- Inadequate symptom relief after 3-6 months of optimal medical therapy
- Patient preference to avoid long-term medication
- Intolerable medication side effects
Minimally Invasive Options 5, 1, 7
Water vapor thermal therapy (Rezūm):
- Office-based procedure under local anesthesia
- Effective for prostates 30-80cc
- Durable results at 4-5 years
- Preserves sexual function
Prostatic urethral lift (UroLift):
- Office-based, preserves ejaculatory function
- Best for prostates <80cc without significant middle lobe
- Rapid symptom improvement
- May need repeat intervention
Temporary implanted prostatic devices (TIPD):
- Newer option for patients unfit for surgery
- Reversible, can be removed 7
Surgical Options (Gold Standard) 5, 1, 7
Transurethral resection of prostate (TURP) remains the gold standard for durable symptom relief in prostates 30-80cc. 5
- TURP: Most durable results, suitable for prostates 30-80cc
- Holmium laser enucleation (HoLEP): Equivalent efficacy to TURP, less bleeding, suitable for any prostate size 7
- Photoselective vaporization (PVP/GreenLight): Lower morbidity, suitable for anticoagulated patients 7
- Transurethral incision of prostate (TUIP): For smaller prostates (<30cc) with bladder neck obstruction
- Open/robotic simple prostatectomy: For very large prostates (>80-100cc)
Surgical selection factors:
- Prostate size and shape (middle lobe presence)
- Anticoagulation status
- Surgeon expertise
- Patient preference regarding sexual function preservation
Stage IV: Complicated BPH - Absolute Indications for Surgery 5, 1, 3
Patients with BPH-related complications require surgical intervention regardless of symptom score. 1
Absolute indications:
- Refractory acute urinary retention (failed trial without catheter)
- Recurrent urinary tract infections attributable to BPH
- Bladder stones secondary to obstruction
- Gross hematuria refractory to medical therapy and attributable to BPH
- Renal insufficiency due to obstructive uropathy
- Large bladder diverticula secondary to obstruction
Management approach:
- Urgent urology referral
- Stabilize complications (catheterization for retention, antibiotics for infection)
- Proceed directly to definitive surgical therapy
- Choice of procedure based on prostate size, patient factors, and local expertise
Pitfall: Don't delay surgery in complicated cases attempting prolonged medical management - risk of irreversible bladder/renal damage.
Special Considerations
Predominant Nocturia 2, 4, 2
Before attributing nocturia solely to BPH, assess with frequency-volume chart:
- Nocturnal polyuria (>33% of 24-hour output at night): Reduce evening fluids, consider desmopressin
- Global polyuria (>3 liters/24 hours): Evaluate for diabetes, heart failure, sleep apnea
- Reduced bladder capacity: Treat with anticholinergics/beta-3 agonists if safe
Monitoring on Medical Therapy 1
- Reassess IPSS and bother at 3-6 months
- Measure PVRU if symptoms worsen
- Annual DRE and PSA (if indicated)
- Consider switching or adding agents if inadequate response
When to Refer to Urology 2, 4, 1
- Suspicious DRE findings (nodules, induration)
- Elevated or rising PSA
- Hematuria (visible or microscopic)
- Recurrent infections
- Palpable bladder/elevated creatinine
- Failed medical therapy
- Patient requesting surgical options
Key Pitfalls to Avoid
Don't use the term "BPH patient" - use "LUTS" as many causes exist beyond prostatic enlargement 2, 4, 2
Don't prescribe 5ARIs for small prostates - ineffective if prostate <30cc 1
Don't add anticholinergics without checking PVRU - risk acute retention if >100-150 mL
Don't ignore nocturia as purely prostatic - often multifactorial requiring separate evaluation 2, 4
Don't delay surgery for absolute indications - attempting medical management risks permanent damage 1, 3
Don't forget to counsel about sexual side effects - major factor in treatment adherence and satisfaction
Don't perform cystoscopy or imaging routinely - reserve for specific indications (hematuria, suspected stricture, stones) 2